Bexlosteride
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | LY 300502 |
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H16ClNO |
| Molar mass | 249.74 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
|
| |
Bexlosteride is a potent and noncompetitive inhibitor of the enzyme 5α-reductase related to finasteride and dutasteride. It is selective for the type I isoform of the enzyme. It advanced to Phase III clinical trials, but development was halted at that stage, and it was never marketed.
See also
|
Drugs used in benign prostatic hyperplasia (G04C)
| |
|---|---|
| 5α-Reductase inhibitors | |
| Alpha-1 blockers | |
| Steroidal antiandrogens | |
| Herbal products | |
| Others | |